Overview of Whole Genome Synthesis MarketThe global Whole Genome Synthesis Market is valued at USD 2.41 Billion in 2024 and is projected to reach a value of USD 12.21 Billion by 2035 at a CAGR ...

Oct. 21, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics ... and controls (CMC) strategy, and global supply management. He ...

Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...

Intellia Therapeutics will find it challenging to survive now that its CRISPR gene-editing treatment has been tied to severe, ...

CRISPR Therapeutics could maintain that momentum thanks to progress with its leading candidates. Spotify Technologies' deep ecosystem continues to expand, and the company is turning profitable. Shares ...

Intellia Therapeutics said it is pausing two late-stage CRISPR gene-editing trials after a patient in one study was hospitalized with liver damage.

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A small S.F. biotech with ties ...

After axing a wide swath of federal research projects and grants, a recent slew of awards offers a glimpse into the kinds of science the second Trump administration wants to back: in vivo cell ...

Europe’s leading cancer conference may be swimming in antibody-drug conjugate data, but AstraZeneca remains convinced that its in-house pipeline sets the pharma apart. The U.K.-based drugmaker earned ...

Explore smart portfolio rebalancing as Comfort Systems USA (FIX) surges. Learn if it's time to shift profits to undervalued ...